Preventive Medication Review Screening Models: Scientific Review and Clinical Implications

Abstract

Preventive medication review screening models are increasingly essential tools in modern healthcare, aiming to optimize pharmacotherapy, reduce polypharmacy, and prevent adverse drug events, particularly in high-risk populations such as the elderly and those with multiple comorbidities. This review synthesizes current evidence on the epidemiology, mechanisms, and clinical implementation of medication review models, highlighting their efficacy, applicability, and relevance in clinical practice. Recent advancements and guideline recommendations are discussed, providing clinicians with a comprehensive framework for integrating these models into routine care.

Introduction

Polypharmacy and inappropriate prescribing remain significant challenges in clinical medicine, driving a surge in adverse drug reactions and healthcare costs globally. Preventive medication review screening models have emerged as systematic approaches to identify, assess, and mitigate medication-related risks before clinical harm occurs. This article critically examines the scientific basis, clinical features, and practical considerations of these models, with a focus on evidence-based strategies for implementation in diverse healthcare settings.

Epidemiology / Disease Burden

The prevalence of polypharmacy commonly defined as the regular use of five or more medications has risen sharply, particularly among older adults and patients with chronic diseases. Studies indicate that up to 50% of elderly patients in developed countries are exposed to polypharmacy, with inappropriate medication use affecting 20-40% of this population. Adverse drug events (ADEs) are responsible for approximately 5-10% of hospital admissions in older adults, underscoring the need for systematic medication review. The burden is further compounded by multimorbidity, fragmented care, and suboptimal communication among healthcare providers, leading to preventable morbidity and mortality.

Pathophysiology

The pathophysiology underlying medication-related harm is multifactorial and complex. Age-related pharmacokinetic and pharmacodynamic changes increase susceptibility to drug-drug interactions, cumulative toxicity, and reduced therapeutic efficacy. Renal and hepatic function decline with age, altering drug metabolism and elimination. Furthermore, the presence of multiple comorbidities often results in complex medication regimens, elevating the risk of errors and adverse outcomes. Preventive medication review models target these mechanisms by systematically evaluating the appropriateness of each medication, potential interactions, and patient-specific factors that may influence drug response.

Risk Factors

Key risk factors for medication-related problems include advanced age, polypharmacy, cognitive impairment, multiple prescribers, transitions of care, and the presence of high-risk medications (e.g., anticoagulants, antidiabetics, psychotropics). Socioeconomic factors, health literacy, and limited access to regular follow-up further increase vulnerability. Identifying these risk factors is integral to stratifying patients and prioritizing medication review interventions.

Clinical Features

Clinically, patients at risk of medication-related harm may present with nonspecific symptoms such as falls, confusion, gastrointestinal disturbances, or functional decline. These manifestations are frequently misattributed to aging or comorbid disease, delaying recognition and intervention. Preventive medication review screening tools employ structured algorithms to flag at-risk individuals before overt clinical deterioration occurs, enabling proactive management.

Diagnosis

Diagnosis of medication-related problems relies on thorough medication reconciliation, patient interviews, and the application of validated screening tools such as the Medication Appropriateness Index (MAI), STOPP/START criteria, and Beers Criteria. Electronic health records (EHRs) and clinical decision support systems (CDSS) have enhanced the accuracy and efficiency of identifying potentially inappropriate prescriptions and drug interactions. Interdisciplinary collaboration among physicians, pharmacists, and nursing staff is crucial for accurate assessment and diagnosis.

Treatment & Management

Management involves deprescribing unnecessary or harmful medications, optimizing therapeutic regimens, and regular monitoring for efficacy and safety. Medication review interventions can be pharmacist-led, physician-led, or collaborative, depending on the healthcare setting. Patient education and shared decision-making are pivotal in ensuring adherence and addressing concerns about medication changes. Follow-up and re-evaluation are recommended, particularly during transitions of care or after significant changes in health status.

Recent Advances / Emerging Therapies

Recent innovations include the integration of artificial intelligence (AI) and machine learning algorithms into medication review processes, facilitating real-time risk prediction and personalized interventions. Mobile health applications and telemedicine platforms are expanding access to medication reviews, especially in remote or underserved populations. Research into biomarkers and pharmacogenomics offers promise for individualized medication optimization, although widespread clinical adoption remains in its infancy.

Guideline Recommendations

International and national guidelines, including those from the American Geriatrics Society and NICE, advocate for routine preventive medication reviews in high-risk groups. Recommendations emphasize the use of standardized screening tools, interdisciplinary collaboration, and the incorporation of medication reviews into routine clinical workflows. The frequency and scope of reviews should be tailored to patient risk profiles, care settings, and resource availability.

Conclusion

Preventive medication review screening models represent a cornerstone of patient safety and quality care in modern medicine. By systematically identifying and addressing medication-related risks, these models reduce preventable harm, improve clinical outcomes, and optimize resource utilization. Ongoing research, technological advances, and robust guideline implementation are essential to further enhance their effectiveness and integration into everyday clinical practice.